Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

AtropEnzymes Engineering new enzymatic platforms for atroposelective C–N bond formation

Coordinator
The University of Manchester, United Kingdom
Runs
1 July 2026 to 31 December 2028
Status
Running
EU funding
€355k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101273816

What the project is doing

In the project's own words, from its summary on CORDIS.

The control of a molecule’s three-dimensional shape has important implications for both its physical and biological properties. Atropisomers—stereoisomers resulting from hindered rotation around a single bond—exhibit axial chirality that can profoundly impact pharmacological properties, making their selective synthesis increasingly important in drug development. Although the number of single-atropisomer pharmaceuticals has significantly grown over the past decade, methods for their stereoselective preparation remain limited, with inefficient and costly chromatographic separations still widely used.

This project addresses this challenge by engineering enzymes capable of novel atroposelective C–N bond-forming reactions, providing direct access to medicinally relevant axially chiral scaffolds. The approach will combine enzymatic desymmetrisation to access electron-rich biaryl atropisomers with atroposelective SNAr reactions to generate electron-poor counterparts. Directed evolution will be applied to enhance activity and selectivity, supported by machine learning to accelerate optimisation and computational protein design to improve enzyme function.

Together, these studies will establish a biocatalytic platform for the efficient, sustainable synthesis of drug-like atropisomeric compounds.

Topics

Who is involved

OrganisationCityCountryRole
The University of ManchesterManchesterUnited KingdomCoordinator
California Institute of TechnologycorpPasadenaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI